PSMF Annexes Guide
- PSMF Annexes Guide
- Introduction
- Why Annexes Exist
- The Real Purpose of Annexes
- Typical Annex Categories
- QPPV Information Annex
- Organisational Structure Annex
- Product Inventory Annex
- Vendor Inventory Annex
- Computerised System Annex
- Audit Programme Annex
- CAPA Annex
- Inspection History Annex
- How Inspectors Use Annexes
- Common Annex Failure Modes
- Annex Governance
- A QPPV Perspective
- What Great Annexes Look Like
- Key Takeaways
- References
Introduction
For many pharmacovigilance professionals, the annexes are the most challenging part of the Pharmacovigilance System Master File (PSMF).
The main body of the PSMF typically changes relatively infrequently.
The annexes often change continuously.
New products are launched.
New vendors are engaged.
Audits are completed.
CAPAs are opened and closed.
Organisational structures evolve.
As a result, annexes frequently become the first part of the PSMF to fall out of date.
This is significant because inspectors often rely on annexes to determine whether the PSMF accurately reflects operational reality.
A mature organisation therefore treats annex maintenance as a governance activity rather than an administrative exercise.
Why Annexes Exist
A common question is:
Why not place all information directly into the main body of the PSMF?
The answer is practicality.
Certain information changes frequently.
Examples include:
- Product inventories
- Vendor inventories
- Audit schedules
- Inspection histories
- Organisational charts
Embedding this information directly within the main body would make the PSMF difficult to maintain.
Annexes solve this problem by separating:
- Stable information
- Dynamic information
A useful way to think about the structure is:
| Component | Purpose |
|---|---|
| Main Body | Explains how the pharmacovigilance system works |
| Annexes | Provide evidence and operational detail |
The main body describes the system.
The annexes demonstrate its current state.
The Real Purpose of Annexes
Many organisations view annexes as attachments.
Inspectors generally do not.
Inspectors often view annexes as the most operationally useful part of the PSMF.
Why?
Because annexes answer practical questions.
For example:
| Inspector Question | Annex Often Used |
|---|---|
| Which products are covered? | Product inventory |
| Which vendors perform activities? | Vendor inventory |
| Who is the QPPV? | QPPV annex |
| Which systems support PV? | System inventory |
| Which audits occurred? | Audit annex |
| What inspections occurred? | Inspection history |
The annexes therefore serve as a bridge between governance descriptions and operational reality.
Typical Annex Categories
Although formats vary, most mature PSMFs contain annexes covering several core areas.
These commonly include:
- QPPV information
- Organisational structures
- Product inventories
- Vendor inventories
- Computerised systems
- Audit programmes
- CAPAs
- Inspection history
The precise structure may differ between organisations, but the underlying objectives are broadly similar.
QPPV Information Annex
The QPPV annex is often reviewed very early during inspections.
Typical information may include:
- Name
- Contact information
- Location
- Qualifications
- Deputy arrangements
Inspectors frequently compare this information against operational reality.
Common deficiencies include:
- Outdated contact details
- Former QPPVs still listed
- Missing deputy arrangements
- Inconsistent information across documents
Because accountability is a fundamental regulatory expectation, errors in this annex can attract disproportionate attention.
Organisational Structure Annex
Organisational charts help explain how pharmacovigilance responsibilities are distributed.
Typical content may include:
- Reporting lines
- Functional groups
- Regional structures
- Affiliate relationships
The objective is not to create a complex corporate chart.
The objective is to demonstrate how pharmacovigilance activities are organised and governed.
Inspectors frequently use these diagrams when selecting interviewees.
Product Inventory Annex
The product inventory is often one of the largest annexes.
It provides visibility regarding:
- Products within scope
- Marketing authorisations
- Jurisdictions
- Regulatory responsibilities
This annex is important because it helps define the scope of the pharmacovigilance system.
A common inspection question is:
Does the product inventory accurately reflect the products for which the organisation is responsible?
Common deficiencies include:
- Missing products
- Withdrawn products still listed
- Incorrect status information
- Delayed updates following acquisitions
Vendor Inventory Annex
Outsourcing is now common across pharmacovigilance.
Many organisations rely upon external providers for:
- Case processing
- Literature surveillance
- Aggregate reporting
- Call centre operations
- Medical review
- Safety databases
The vendor annex provides visibility regarding these relationships.
A mature vendor inventory often includes:
- Vendor name
- Activity performed
- Criticality
- Oversight owner
- Agreement status
Inspectors frequently compare vendor inventories against contractual records.
Missing vendors often generate questions regarding oversight.
Computerised System Annex
Modern pharmacovigilance systems depend heavily upon technology.
The system annex typically identifies:
- Safety databases
- Document management systems
- Signal management tools
- Reporting platforms
- Compliance tracking tools
Inspectors use this information to understand:
- Data flows
- Data ownership
- System dependencies
A well-maintained inventory improves transparency and inspection readiness.
Audit Programme Annex
Audits represent an important mechanism for assessing whether the pharmacovigilance system functions effectively.
The audit annex may include:
- Planned audits
- Completed audits
- Audit schedules
- Audit coverage
Inspectors frequently review audit information to understand how the organisation verifies compliance.
The objective is not merely to demonstrate that audits occur.
The objective is to demonstrate that the audit programme is risk-based and effective.
CAPA Annex
A mature PSMF often provides visibility of significant CAPAs affecting the pharmacovigilance system.
Examples may include:
- Inspection CAPAs
- Audit CAPAs
- Compliance CAPAs
- Process improvement CAPAs
Inspectors often use CAPA information to assess whether identified issues are effectively managed.
A recurring finding is the presence of repeated issues despite previous CAPAs.
This may indicate ineffective root cause analysis.
Inspection History Annex
Inspection history provides context regarding previous regulatory interactions.
Typical information may include:
- Inspection dates
- Authorities involved
- Scope
- Outcomes
- Significant observations
This information helps inspectors understand the organisation's compliance history.
It also supports organisational learning.
How Inspectors Use Annexes
Inspectors rarely review annexes in isolation.
Instead, they use annexes to verify statements made elsewhere.
For example:
| Main Body Statement | Annex Verification |
|---|---|
| Vendor oversight exists | Vendor inventory |
| QPPV appointed | QPPV annex |
| Audit programme operates | Audit annex |
| Products are monitored | Product inventory |
This is one reason annex quality is so important.
The annexes often determine whether the main body appears credible.
Common Annex Failure Modes
Most annex-related findings arise from a relatively small number of causes.
Outdated Information
The most common problem.
Examples include:
- Former vendors
- Obsolete products
- Retired systems
- Historical organisational charts
Missing Information
Examples include:
- Missing vendors
- Missing products
- Missing inspections
- Missing CAPAs
Ownership Uncertainty
Nobody clearly owns the annex.
Updates occur inconsistently.
Manual Maintenance Burden
Large inventories become difficult to maintain.
Errors accumulate gradually.
Annex Governance
High-performing organisations treat annexes as governed inventories rather than static attachments.
Characteristics commonly include:
- Defined ownership
- Update procedures
- Review schedules
- Change control integration
- Periodic verification
This significantly improves long-term quality.
A QPPV Perspective
For QPPVs, annexes often provide the fastest route to understanding a pharmacovigilance system.
Reviewing:
- Product inventories
- Vendor inventories
- Organisational structures
- Audit programmes
can quickly reveal:
- Scope
- Complexity
- Governance maturity
- Compliance risks
This is particularly valuable during:
- New QPPV appointments
- Acquisitions
- Organisational restructuring
- Inspection preparation
What Great Annexes Look Like
The best annexes are:
- Accurate
- Current
- Complete
- Easy to navigate
- Clearly owned
- Consistently maintained
Importantly, they remain useful between inspections.
A strong annex framework supports governance every day, not merely during regulatory inspections.
Key Takeaways
- Annexes provide the operational detail supporting the PSMF.
- They separate dynamic information from the main body of the document.
- Inspectors frequently use annexes to verify statements contained elsewhere in the PSMF.
- Product inventories and vendor inventories are among the most critical annexes.
- Most annex findings arise from outdated or incomplete information.
- Mature organisations manage annexes through defined ownership and governance processes.
- Well-maintained annexes significantly improve inspection readiness and QPPV oversight.
References
- EMA Good Pharmacovigilance Practices (GVP) Module II – Pharmacovigilance System Master File.
- EMA Good Pharmacovigilance Practices (GVP) Module I – Pharmacovigilance Systems and Their Quality Systems.
- EMA Good Pharmacovigilance Practices (GVP) Module III – Pharmacovigilance Inspections.
- Regulation (EC) No 726/2004.
- Directive 2001/83/EC.
- Commission Implementing Regulation (EU) No 520/2012.
- EMA Questions and Answers on Pharmacovigilance System Master Files.